Development and Validation of a Novel Mobility Test for Rod-Cone Dystrophies: From Reality to Virtual Reality.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
16 Jul 2023
Historique:
received: 09 02 2023
revised: 29 06 2023
accepted: 30 06 2023
pubmed: 13 7 2023
medline: 13 7 2023
entrez: 12 7 2023
Statut: aheadofprint

Résumé

To validate a novel mobility test (MOST, MObility Standardized Test) and performance outcomes in real (RL) and virtual (VR) environments to be used for interventional clinical studies in order to characterize vision impairment in rod-cone dystrophies, also known as retinitis pigmentosa (RP). Prospective, interventional, noninvasive, reliability and validity analysis. We designed MOST to be used in both VR and RL and conducted 3 experimental studies with 89 participants to (1) validate the difficulty of the mobility courses (15 controls), (2) determine the optimal number of light levels and training trials (14 participants with RP), and (3) validate the reproducibility (test-retest), reliability (VR/RL), sensitivity, and construct/content validity of the test (30 participants with RP and 30 controls). A comprehensive ophthalmologic examination was performed in all subjects. Outcomes of interest included MOST performance score, visual acuity, contrast sensitivity, dark adaptation thresholds, visual field parameters, and correlation between the performance score and visual function. The mobility courses exhibited statistically similar difficulty, and 5 trials are sufficient to control for the learning effect. MOST is highly reproducible (test-retest correlations >0.98) and reliable (correlations VR/RL = 0.98). MOST achieved a discrimination between participants with RP and controls (accuracy >95%) and between early and late stages of the disease (82.3% accuracy). The performance score is correlated with visual function parameter (0.57-0.94). MOST is a validated mobility test, with the controlled learning effect, excellent reproducibility, and high agreement between RL and VR conditions, as well as sensitivity and specificity to measure disease progression and therapeutic benefit in rod-cone dystrophies.

Identifiants

pubmed: 37437832
pii: S0002-9394(23)00279-9
doi: 10.1016/j.ajo.2023.06.028
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-54

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Colas Nils Authié (CN)

From the Streetlab (C.N.A., M.P., A.T., A.D., A.Z., C.C.), Paris, France. Electronic address: colas.authie@streetlab-vision.com.

Mylène Poujade (M)

From the Streetlab (C.N.A., M.P., A.T., A.D., A.Z., C.C.), Paris, France.

Alireza Talebi (A)

From the Streetlab (C.N.A., M.P., A.T., A.D., A.Z., C.C.), Paris, France; Institut de la Vision, Sorbonne Universités, INSERM, CNRS (A.T., I.A., J.-A.S.), Paris, France.

Alexis Defer (A)

From the Streetlab (C.N.A., M.P., A.T., A.D., A.Z., C.C.), Paris, France.

Ariel Zenouda (A)

From the Streetlab (C.N.A., M.P., A.T., A.D., A.Z., C.C.), Paris, France.

Cécilia Coen (C)

From the Streetlab (C.N.A., M.P., A.T., A.D., A.Z., C.C.), Paris, France.

Saddek Mohand-Said (S)

Hôpital National de la Vision des Quinze-Vingts, DHU Sight Restore, Centre de Référence Maladies Rares REFERET, INSERM-DHOS CIC 1423 (S.M.-S., P.C.-R., I.A., J.-A.S.), Paris, France.

Philippe Chaumet-Riffaud (P)

Hôpital National de la Vision des Quinze-Vingts, DHU Sight Restore, Centre de Référence Maladies Rares REFERET, INSERM-DHOS CIC 1423 (S.M.-S., P.C.-R., I.A., J.-A.S.), Paris, France.

Isabelle Audo (I)

Institut de la Vision, Sorbonne Universités, INSERM, CNRS (A.T., I.A., J.-A.S.), Paris, France; Hôpital National de la Vision des Quinze-Vingts, DHU Sight Restore, Centre de Référence Maladies Rares REFERET, INSERM-DHOS CIC 1423 (S.M.-S., P.C.-R., I.A., J.-A.S.), Paris, France.

José-Alain Sahel (JA)

Institut de la Vision, Sorbonne Universités, INSERM, CNRS (A.T., I.A., J.-A.S.), Paris, France; Hôpital National de la Vision des Quinze-Vingts, DHU Sight Restore, Centre de Référence Maladies Rares REFERET, INSERM-DHOS CIC 1423 (S.M.-S., P.C.-R., I.A., J.-A.S.), Paris, France; Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA (J.-A.S.).

Classifications MeSH